Guarneri V, Dieci MV, Griguolo G, Miglietta F, et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. Eur J Cancer 2021;153:133-141.
PMID: 34153715